Author: sHq_LoGiNz

By: Beth Szymkowski
Contributor

At first glance, The Way We Wore could be mistaken for an ordinary Los Angeles secondhand store with a warehouse vibe. Huge windows cast warm light onto cement floors and racks hung with an eclectic mix of clothing and accessories. But a closer look reveals that it is more like a museum of fashion history. Some items date back to the early 1900s. There’s a rack of Chanel. Another of Pucci. Orange and red Bakelite jewelry fills a shelf in a glass case. Doris Raymond, a longtime leader in the world of high-end vintage fashion, carefully curates every item in the showroom.

After 45 years in the vintage business, Raymond is suddenly right at the forefront of fashion. The resale market is growing fast, driven in large part by younger shoppers. Nearly half of Gen Z and millennials say they search for secondhand or used items more often than they used to, compared with roughly a quarter of boomers, according to Mastercard’s December 2025 Consumer Collective Financial Sentiment survey.

And an upcoming analysis by the Mastercard Economics Institute shows Finland, France and the U.S. leading the way, with circular spending accounting for 10.5% of clothing store spending in Finland, with resale the vast majority.

Part of the appeal is that reusing items is better for the environment, and younger generations say they’re willing to pay more for goods that align with their values. Those sustainability concerns, along with tariff-related price increases on imported goods like fast fashion, will likely feed the circular economy trend.

“We’re watching circular spending move from the margins to the mainstream,” says Ellen Jackowski, chief sustainability officer at Mastercard. “It’s not a fad; it’s economics. When value meets values, everybody wins: consumers, merchants, and the planet.”

Secondhand fashion is now a $256 billion global business on track to reach $367 billion by 2029. Raymond’s corner of the market, luxury resale, which includes a handful of e-commerce giants, made up 27% of online luxury apparel spending in 2024, while mass-market resale climbed to 5.4% in 2025, according to the Mastercard Economics Institute’s 2025 report on fashion and the circular economy. And in Los Angeles, where Raymond is based, circular fashion makes up 7% of online apparel spending, the report says.

“I’m an accidental sustainable person,” Raymond says with a laugh while taking me on a tour of her appointment-only showroom. She has always been drawn to older clothes that were made with a level of care and quality that fast fashion lacks. “Why throw away money on something that’s not made to last, even if it’s four times the price? If you buy a classic, something that’s not trendy, it’ll be with you for a long time.”

Raymond, who starred in the Smithsonian Channel series “L.A. Frock Stars,” became interested in vintage clothing as a teenager looking for an inexpensive way to express her unique style. She grew her passion into a business in the San Francisco area, eventually opening a store, doing vintage clothing shows and renting pieces to the film and television industry. She moved to Los Angeles in 2004 and, in addition to her brick-and-mortar shop, now maintains a YouTube channel with more than 100 episodes and an online store.

Unlike many high-end vintage shops that sell only clothing from the past 30 or so years, Raymond’s showroom is lovingly filled with items from the last century as well as more popular items from recent decades. Customers might find Gucci cage stiletto booties perched on shelves near Emanuel Ungaro pumps, but her collection is not based on big-name designers only. “A label isn’t everything,” she says, pointing out a dress’s intricate handmade lace and the artistry of a slyly whimsical Anthony Ferrara chain-mail belt with two hand-shaped clasps. “If something transcends time, that’s what matters.”

Sharing her passion is part of why Raymond offers deep dives into fashion history for customers, including through a curated Priceless Experience for Mastercard cardholders. She might show guests an elegant 1920s flapper dress and compare it to a 1960s minidress, explaining how both styles emerged as a reaction to societal change. In the 1920s, shortly after women gained the right to vote, clothing evolved to reflect their newfound freedoms: Hemlines rose and the restrictive corsets of earlier eras were abandoned. The Civil Rights and anti-war movements of the 1960s ushered in a similarly liberated style. After the Priceless Experiences, participants frequently peruse the showroom with newfound appreciation for the items they see.

“My biggest joy is inspiring other people,” Raymond says. “That’s why I’m doing the Mastercard events. Every single exoerience that’s happened, I’ve enjoyed it as much as the people who came. I know they leave feeling really, really good.”

Continue reading here

Follow along Mastercard’s journey to connect and power an inclusive, digital economy that benefits everyone, everywhere.

Key points

• The first FDA-approved treatment for a chronic liver infection
• The first FDA-approved treatment for Hepatitis D virus in adults with chronic liver disease
• CVS Caremark’s Clinical Pipeline Services team tracks what’s ahead ​by ​translating complex drug approvals into practical information about what may matter for ​​​patient care​.

Originally published on CVS Health Company News

New treatments take years of research, clinical trials, and regulatory review before reaching patients. Several therapies approaching FDA decisions this spring could expand treatment options for people managing a range of conditions.

CVS Caremark’s Clinical Pipeline Services team — made up of licensed clinical pharmacists and analysts — monitors new therapies moving through the drug pipeline and evaluates what those approvals could mean for members. The team’s latest Drugs to Watch report identifies several notable therapies with decisions expected between April and June 2026, including:

• A new oral option for patients with treatment-resistant hypertension
• ​​​A more convenient, at-home format for early Alzheimer’s disease treatment that avoids lengthy IV infusions​​​​​​​​​​
• The first FDA-approved treatment for a chronic ​​​​liver infection
• An additional non-nicotine option for adults looking to quit smoking

The following provides a closer look at each drug: what it is, why it matters, and how it could expand treatment options for patients.

Baxdrostat: a new mechanism for treating high blood pressure

Baxdrostat is an oral medication being reviewed for adults whose blood pressure remains uncontrolled despite treatment with multiple other blood pressure medications, a condition known as treatment-resistant hypertension. It would be used as an add-on to existing treatments. What makes Baxdrostat stand out is how it works: it inhibits aldosterone synthase (an enzyme involved in regulating blood pressure), an approach not currently available in approved treatments for this condition.

​​Treatment-resistant hypertension is blood pressure that stays above a target level even after trying at least three different medications at the right doses. ​​​​​A new mechanism may offer another way to control the condition, which could be significant for people who have run out of alternatives. If approved, it would be the first option of its kind for this population.

Status: Pending FDA approval 6/2/2026.

Leqembi Iqlik: an at-home treatment for Alzheimer’s

Leqembi Iqlik is an injectable form of Leqembi, a therapy already FDA-approved for the treatment of early Alzheimer’s disease. The existing version is given through an IV infusion every two weeks over an initial 18-month course. Leqembi Iqlik is already approved for ongoing treatment after that initial IV phase. ​​If approved for this use, it would become the first therapy of its kind that patients could administer at home weekly from the start of treatment.

The shift to a weekly injection at home is what makes this approval worth watching. For patients and caregivers navigating early Alzheimer’s disease, reducing the burden of getting to a treatment facility could make a difference  if and how people pursue this type of care.

Status: Pending FDA approval 5/24/2026.

Hepcludex: a possible first FDA-approved treatment for chronic hepatitis D virus infection in adults with chronic liver disease

Hepcludex (bulevirtide) is an injectable treatment being reviewed for chronic hepatitis D virus (HDV) infection in adults with chronic liver disease. If approved, it would be the first FDA-approved treatment for HDV, a condition with no FDA-approved treatment in the United States.

For patients living with a condition that has had no approved treatment, this could be a significant milestone. While taking Hepcludex on its own may allow some patients to eventually stop treatment, the data suggests combining it with another medication called pegylated interferon produces meaningfully better results — an important detail for providers and patients following this potential approval.

Status: Pending FDA approval 5/22/2026.

Cytisinicline: another tool in the fight to quit smoking

Cytisinicline is an oral therapy being reviewed for the treatment of nicotine dependence in adults seeking to quit smoking. It would join Varenicline (e.g., Chantix) and Bupropion as prescription options that don’t rely on nicotine replacement. If approved, it would be administered as part of either a six- or 12-week initial treatment course.

Quitting smoking is notoriously difficult, and one reason is that different approaches work for different people. More options increase the chances that patients can find an approach that works for them.

Status: Pending FDA approval 6/20/2026.

The bigger picture: what this spring’s pipeline says about where care is headed

The therapies expected this spring span different conditions and work in different ways. But each represents a meaningful step forward for patients who need care — whether that’s a new option where existing treatments haven’t worked, a first approval in a condition that has never had an approved treatment, or a more accessible way to take a therapy that already exists. For patients and providers alike, having more options means more room to find an approach that works.

Coverage will vary by plan, and not every approval will be relevant to every member. But staying informed about the pipeline is valuable. If any of these conditions affect you or someone you care for, it could be worth starting a conversation with your provider about what may be on the horizon.

CVS Caremark’s Clinical Pipeline Services team will continue tracking what is next so ​CVS clients and their plan ​members can stay informed as new therapies move closer to approval.

Learn more about the team and the Q2 2026 Pipeline Drugs to Watch Report.

As previously seen on the CSRHub blog.

By Bahar Gidwani

We are pleased to share that our partners at Brand Finance have recently published research that incorporates CSRHub ESG data.

The Brand Finance Sustainability Perceptions Index 2026 uses CSRHub ESG ratings and data to support analysis of corporate sustainability performance and ESG trends across industries and regions. This collaboration demonstrates how ESG data can be used not only for internal benchmarking and reporting, but also for broader market analysis and brand valuation work.

 

We are always excited to see CSRHub data used in new research, reports, and analytical tools that help improve transparency and understanding of corporate sustainability performance.

You can read the full Brand Finance article here.

Brand Finance is a global leader in brand valuation and brand strategy, and their sustainability and ESG analysis continues to highlight the growing importance of environmental, social, and governance performance in corporate value and reputation.

CSRHub provides ESG ratings, benchmarking tools, and data feeds that support:

• Benchmarking to improve ratings
• Supply chain and vendor assessment
• Regulatory readiness
• Investment and risk analysis
• Academic and research applications

If you are interested in using CSRHub data for research, reporting, or analytics, please contact us or explore our tools and data offerings on our website.

Bahar Gidwani is CTO and Co-founder of CSRHub. He has built and run large technology-based businesses for many years. Bahar holds a CFA, worked on Wall Street with Kidder, Peabody, and with McKinsey & Co. Bahar has consulted to a number of major companies and currently serves on the board of several software and Web companies. He has an MBA from Harvard Business School and an undergraduate degree in physics and astronomy. He plays bridge, races sailboats, and is based in New York City.

About CSRHub

CSRHub offers the most comprehensive global set of expert consensus sustainability ratings, information, and tools. Clients use CSRHub’s decisive data platform for global benchmarking, supply and value chain risk assessment and compliance readiness solutions. Founded in 2007, CSRHub covers over 60,000 public and private companies, and provides ESG performance scores on 42,000 companies from 134 industries in 158 countries. Our Big Data platform uses algorithms to aggregate, normalize and weight ESG metrics from 1,000 sources to produce a strong consensus signal on corporate sustainability performance.

Interested in learning more about CSRHub?

• Largest reduction to date compared to company’s 2019 base year
• Zero-carbon energy provides 41.1% of the company’s electricity.

Baker Hughes (NASDAQ: BKR), an energy technology company, reported a 36.9% absolute emissions reduction in scope 1 and 2 greenhouse gas (GHG) emissions compared to its 2019 baseline, marking the largest emissions reduction to date, according to its latest sustainability report released Tuesday. The company recorded an absolute reduction in scope 1 and 2 GHG emissions from the 2019 base of 36.9%, and operational emissions intensity of scope 1 and 2 GHG emissions reduced by 45.8% from the 2019 base while maintaining profitable growth. Utilization of renewable energy and operational efficiencies contributed to 49.0% reduction in combined scope 1 and 2 facility emissions from its 2019 base.

These results reflect Baker Hughes’ continued progress toward its sustainability goals, supported by strong governance and a unified “People First” culture.

“Sustainability underpins The Energy Equation™, ensuring that both industrial outcomes and energy sources are more efficient, more reliable, and more secure,” said Baker Hughes Chairman and CEO Lorenzo Simonelli. “As we develop solutions for both traditional and new energy sources, we remain committed to integrity, transparency, and accountability in support of a safer, cleaner, and more secure lower‑carbon future.”

“Our 2025 sustainability report shows the largest reduction in absolute operational emissions since our net‑zero commitment in 2019, demonstrating that profit and purpose can go together,” Baker Hughes Chief Sustainability Officer Allyson Anderson Book said. “We’re helping advance sustainability for our customers and within our operations as we remain committed to achieving our net‑zero goal. Through people‑driven initiatives like Carbon Out, sustainability considerations are embedded across our business.” 

Key Sustainability Performance Highlights 

Climate and environmental performance

• Achieved a 36.9% absolute reduction and 45.8% reduction in emissions intensity in scope 1 and 2 GHG emissions from the 2019 base year
• Reduced total waste generated by 29.0% compared to 2022 baseline, with 61,270 metric tons of waste recycled
• Completed a record 856 life cycle assessments (LCAs) – 52.9% increase year over year – helping customers better understand both the embedded emissions and operations (in use) emissions of its solutions

People, safety, and culture

• Completed more than 1.65 million safety observations, with a total recordable incident rate of 0.25
• Conducted the first‑ever global all‑employee engagement survey, delivered in 64 languages with an approximately 63% completion rate, advancing a unified listening strategy to drive meaningful change
• Engaged over 1,000 employees working on approximately 1,500 active scope 1 and 2 emissions‑reduction projects through the Carbon Out initiative

Community impact

• Supported over 900 charities worldwide
• More than 2,100 employees contributed over 45,000 volunteer hours in the communities where Baker Hughes lives and operates

As a participant in the UN Global Compact – a voluntary leadership platform for the development, implementation, and disclosure of responsible business practices – Baker Hughes remains committed to transparency with two independent audits of its annual sustainability report. In 2025, the company was awarded Best Sustainability Reporting by Governance Intelligence.

Baker Hughes’ corporate sustainability report is prepared with reference to the Global Reporting Initiative (GRI) standards and the GHG Protocol. The report is supplemented with detailed indices in respect of the Sustainability Accounting Standards Board (SASB) disclosures relevant to Baker Hughes, the Task Force on Climate-related Financial Disclosure (TCFD) recommendations, and CDP disclosures.

Access the full 2025 Corporate Sustainability Report here.

About Baker Hughes
Baker Hughes (NASDAQ: BKR) is an energy technology company that provides solutions to energy and industrial customers worldwide. Built on a century of experience and conducting business in over 120 countries, our innovative technologies and services are taking energy forward – helping make it safer, cleaner, and more efficient for people and the planet. Visit us at bakerhughes.com.

### 

For more information, please contact: 

Media Relations 
Adrienne M. Lynch
+1-713-906-8407
adrienne.lynch@bakerhughes.com

Read More